Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 18, 2025
Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models
Victoria M Ettorre, Cem Demirkiran, Stefania Bellone, et al.
International Journal of Molecular Sciences
|
May 27, 2023
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
Stefania Bellone, Blair McNamara, Levent Mutlu, et al.
Gynecologic Oncology
|
October 15, 2025
Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis
Victoria M Ettorre, Stefania Bellone, Natalia Buza, et al.
Gynecologic Oncology
|
May 7, 2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Victoria M Ettorre, Stefania Bellone, Michelle Greenman, et al.
Cancer Research Communications
|
August 27, 2025
Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomas
Niccolo G Santin, Namrata Sethi, Stefania Bellone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 18, 2025
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models
Victoria M Ettorre, Beatrice Conca, Cem Demirkiran, et al.
Gynecologic Oncology
|
July 9, 2024
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
Blair McNamara, Michelle Greenman, Stefania Bellone, et al.
Cancer Research Communications
|
April 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma
Michelle Greenman, Cem Demirkiran, Stefania Bellone, et al.
Gynecologic Oncology
|
June 29, 2025
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
Michelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Cancer Medicine
|
September 6, 2024
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer
Tobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 18, 2025
Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models
Victoria M Ettorre, Cem Demirkiran, Stefania Bellone, et al.
International Journal of Molecular Sciences
|
May 27, 2023
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
Stefania Bellone, Blair McNamara, Levent Mutlu, et al.
Gynecologic Oncology
|
October 15, 2025
Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis
Victoria M Ettorre, Stefania Bellone, Natalia Buza, et al.
Gynecologic Oncology
|
May 7, 2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Victoria M Ettorre, Stefania Bellone, Michelle Greenman, et al.
Cancer Research Communications
|
August 27, 2025
Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomas
Niccolo G Santin, Namrata Sethi, Stefania Bellone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 18, 2025
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models
Victoria M Ettorre, Beatrice Conca, Cem Demirkiran, et al.
Gynecologic Oncology
|
July 9, 2024
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
Blair McNamara, Michelle Greenman, Stefania Bellone, et al.
Cancer Research Communications
|
April 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma
Michelle Greenman, Cem Demirkiran, Stefania Bellone, et al.
Gynecologic Oncology
|
June 29, 2025
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
Michelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Cancer Medicine
|
September 6, 2024
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer
Tobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, et al.
Page
of 4